WEKO3
アイテム
{"_buckets": {"deposit": "2e78ce0c-361b-4ff0-a65d-ee9447897490"}, "_deposit": {"created_by": 1, "id": "81596", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "81596"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00081596", "sets": ["29"]}, "author_link": ["924080", "924073", "924082", "924069", "924078", "924068", "924074", "924066", "924075", "924076", "924072", "924077", "924070", "924081", "924065", "924064", "924079", "924063", "924067", "924071"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2020-05-15", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "[Purpose] In the QST hospital, carbon ion radiotherapy (CIRT) using spot-scanning was started in 2011. In order to check each individual CIRT treatment plan and its treatment delivery, the scanning system and its treatment planning system require dosimetric patient-specific Quality Assurance (PQA) before CIRT. We report results of PQA in half year of 2017.\n[Methods] For the PQA, all the planned beams are recalculated on a water phantom with treatment planning software. The recalculated dose distributions are compared with the measured distributions using a 2D ionization chamber array at three depth, including 95% area of prescription dose. These are evaluated using 3%/3 mm gamma criteria with a pass threshold of 90%. We analyzed PQA results for about 1500 shots from September 2017 to March 2018, evaluated the pass rate for 10 disease sites with various target volume, energy and measurement depth.\n[Results] The pass rate for prostate, head and neck, and bone and soft tissue were 95.9%, 99.3%, and 91.5%, respectively. 95.9% of lung plans with low energy beam passed. Overall, 95% of the measured beams for all shots passed the gamma criteria, and were consistent with the plan. Although the rest of 5% failed the criteria, there were no dependence of measurements depth and disease sites in these failures.\n[Conclusion] The results of the PQA in the second half of FY2017 was analyzed. The overall quality assurance measurement passing rate was 95% for the gamma index criteria of 3%/3 mm. It was obvious that there was no disease sites or target dependency in these pass rates. Therefore, we could ensure the safety of the CIRT treatment plans.\n", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "第119回日本医学物理学会学術大会", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "猪俣, 麻美"}], "nameIdentifiers": [{"nameIdentifier": "924063", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鈴木, 優維"}], "nameIdentifiers": [{"nameIdentifier": "924064", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "勝間田, 匡"}], "nameIdentifiers": [{"nameIdentifier": "924065", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "中島, 猛雄"}], "nameIdentifiers": [{"nameIdentifier": "924066", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "古市, 渉"}], "nameIdentifiers": [{"nameIdentifier": "924067", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "山岡, 恵士"}], "nameIdentifiers": [{"nameIdentifier": "924068", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "菅, 満喜人"}], "nameIdentifiers": [{"nameIdentifier": "924069", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "山本, 淳史"}], "nameIdentifiers": [{"nameIdentifier": "924070", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "水野, 秀之"}], "nameIdentifiers": [{"nameIdentifier": "924071", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "河野, 良介"}], "nameIdentifiers": [{"nameIdentifier": "924072", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Asami, Inomata", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924073", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yui, Suzuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924074", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masashi, Katsumata", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924075", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakajima, Takeo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924076", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wataru, Furuichi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924077", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Keisi, Yamaoka", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924078", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Makito, Suga", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924079", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Atsushi, Yamamoto", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924080", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hideyuki, Mizuno", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924081", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ryosuke, Kohno", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "924082", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Evaluation of Patient-specific Quality Assurance for Spot-Scanning Carbon Ion Radiotherapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Evaluation of Patient-specific Quality Assurance for Spot-Scanning Carbon Ion Radiotherapy"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/81596", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-01-08"}, "publish_date": "2021-01-08", "publish_status": "0", "recid": "81596", "relation": {}, "relation_version_is_last": true, "title": ["Evaluation of Patient-specific Quality Assurance for Spot-Scanning Carbon Ion Radiotherapy"], "weko_shared_id": -1}
Evaluation of Patient-specific Quality Assurance for Spot-Scanning Carbon Ion Radiotherapy
https://repo.qst.go.jp/records/81596
https://repo.qst.go.jp/records/81596059fee55-3e4a-4c8a-b4ed-db63d62abfb0
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-01-08 | |||||
タイトル | ||||||
タイトル | Evaluation of Patient-specific Quality Assurance for Spot-Scanning Carbon Ion Radiotherapy | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
猪俣, 麻美
× 猪俣, 麻美× 鈴木, 優維× 勝間田, 匡× 中島, 猛雄× 古市, 渉× 山岡, 恵士× 菅, 満喜人× 山本, 淳史× 水野, 秀之× 河野, 良介× Asami, Inomata× Yui, Suzuki× Masashi, Katsumata× Nakajima, Takeo× Wataru, Furuichi× Keisi, Yamaoka× Makito, Suga× Atsushi, Yamamoto× Hideyuki, Mizuno× Ryosuke, Kohno |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | [Purpose] In the QST hospital, carbon ion radiotherapy (CIRT) using spot-scanning was started in 2011. In order to check each individual CIRT treatment plan and its treatment delivery, the scanning system and its treatment planning system require dosimetric patient-specific Quality Assurance (PQA) before CIRT. We report results of PQA in half year of 2017. [Methods] For the PQA, all the planned beams are recalculated on a water phantom with treatment planning software. The recalculated dose distributions are compared with the measured distributions using a 2D ionization chamber array at three depth, including 95% area of prescription dose. These are evaluated using 3%/3 mm gamma criteria with a pass threshold of 90%. We analyzed PQA results for about 1500 shots from September 2017 to March 2018, evaluated the pass rate for 10 disease sites with various target volume, energy and measurement depth. [Results] The pass rate for prostate, head and neck, and bone and soft tissue were 95.9%, 99.3%, and 91.5%, respectively. 95.9% of lung plans with low energy beam passed. Overall, 95% of the measured beams for all shots passed the gamma criteria, and were consistent with the plan. Although the rest of 5% failed the criteria, there were no dependence of measurements depth and disease sites in these failures. [Conclusion] The results of the PQA in the second half of FY2017 was analyzed. The overall quality assurance measurement passing rate was 95% for the gamma index criteria of 3%/3 mm. It was obvious that there was no disease sites or target dependency in these pass rates. Therefore, we could ensure the safety of the CIRT treatment plans. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 第119回日本医学物理学会学術大会 | |||||
発表年月日 | ||||||
日付 | 2020-05-15 | |||||
日付タイプ | Issued |